KRAS and neoplasm: These studies highlighted how LKB1 inactivation is significantly associated with KRAS mutations compared to TP53 deletion and that co-occurrence of KRAS mutation with inactivation of LKB1, TP53 or CDKN2A/B genes generates different tumor subsets with distinct biology, immune profiles, and therapeutic vulnerabilities [29].